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ABSTRAK
Endothelial progenitor cells (EPc| adalah sel yang berasal dari sumsum tulang dan bersirkulasi di darah
perifer. Sel ini memitiki karakteristik mirip stem cell (sel punca), tetapi dengan kemampuan berproliferasi
dan berdiferensiasi yang lebih terbqtas. Penemuan EPC telah mengubah paradigma lama dalam 
bidang
biologi vaskylar do, op^boryg ihplikasi besar dalam dunia kedokteran karena EPC dapat memediasi 
proses
vaskulogenesis dan menjaga integritas pembuluh darah. Peningkatan jumlah EPC dalam sirkulasi meniadi
penting karena berkc)relasi positif dengan reendotelialisasi dan neovaskularisasi yang berhubungan 
erat
dengan kesehqtan kardiovaskular Dengan demikian, EPC berpotensi d.igunakan untuk 
terapi penyakit akibat
disfungsi endotel.
Kuta kunci: endothelial progenitor cell, disfungsi endotel, vaskulogenesis' reendotelialisasi'
ABSTRACT
Endotheliat progenitor cells (Epc| are cell derivedfrom bone marrow and the cells circulate in peripheral
blood. These cells have characteristics similar to stem cells, but their ability to proliferate 
and dffirentiate is
more limited. EPC discovery has changed the old paradigm in thefietd of vascular biologt and 
it brings huge
implications in medicine as EPCs can mediate the processes of vasculogenesis and 
maintain the vascular integrity'
Increasing amount oJ'EpC in the circulation is important since it has positive correlation 
with reendothelialization
and neovascularization and they are closely linked to cardiovascular health' Thus' 
EPC could potentially be
usedfor treatment ofdisease caused by endothelial dysfunction'
Kev words: endothelial progenitor cell, endothelial dysfunction' vasculogenesis' reendothelialization'
I
INTRODUCTION
Endothelial progenitor cells (EPCs) are cells
derived from bone maffow and they circulate in
peripheral blood. The cells have characteristics
similar to stem cells, but their ability to proliferate
and differentiate is more limited, i'e' they only
can differentiatd into endothelial cells'r'2
In 1991, Asahara et al3 has successfully
isolated EPC from peripheral blood for the first
time. The cells have positive surface antigen
for mucosialin (CD34) and vascular endothelial
growth factor receptor-2 (VEGFR-2/FLK-1)'
In vitro, the cells have a potency to develop
into mature endothelial cells and in vivo, they
have roles in neoangiogenesis. Shi et ala have
demonstrated that mononuclear cells which
contain bone-marrow-derived-CD34* surface
antigen can be mobilized to peripheral circulation
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and can differentiate into mature endothelial
cells. Since the discovery mononuclear cells
of peripheral blood which have CD34+ surface
antigen are believed to be derived from the
bone marrow and the cells are originated from
the same precursor of hematopoetic stem cells
(hemangioplast) since both of them show the
same surface antigen, i.e. which is positive to
CD34, prominin- 1 (CDl33) and FLK-I.rr
The EPC discovery has changed the old
paradigm in the field ofvascular biology, which
believes that the process of vasculogenesis
exclusively occurs only during embryogenesis.
Some evidences indicate that postnatal
neovascularization is not only derived from
proliferation, migration and remodeling of
endothelial cells on vascular wall (angiogenesis),
but it also involve EPC recruitment from bone
marrow, a process that has been known as
vasculogenesis.6-8 The discovery has brought
huge implications in medicine as EPCs can
mediate the processes of va*sculogenesis and
maintain the vascutar integlity.l
Risk factors for cardiovascular diseases are
smoking, hypertension, diabetes mellitus and
dyslipider4ia, which show reduced number of
EPCs. Thus, EPC could'potentially be used for
treatment of ischemic disease by mechanisms of
vasculogenesis through reendothelialization and
neovascularization. Both are the key process to
improve the quality ofblood vessels and to repair
tissue ischemia.s'e
MOBILIZATION, DIFFERENTIATION AND EPC
HOMING
The main source of EPCs is bone marrow,
but the cells can also be isolated from peripheral
and umbilical blood. In normal condition, the
number of EPCs from those various sources is
very limited; while the mobilization from bone
marrow and the number in the circulation are
extremely affected by endogenous, exogenous
factors as well as physiological and pathological
conditions.6,ro rr
The rdlease of EPCs from bone marrow is
affected by various growth factors, enzymes,
ligands and surface receptors. The natural
response ofbody tissues when there is hypoxia
is increasing the production and secretion of
factors that stimulate neovascularization in
order to reduce hypoxia. In hypoxia state,
the hypoxia-inducible transcription factor-
1c (HIF-1cr) induces transcription of various
proangiogenic proteins such as VEGF, stromal
cell-derived factor-1 (SDF-l) and monocytes
chemotatic protein- 1 (MCP- 1), which will
actively recruit EPCs from bone marrow to the
circulation and then guide them to hypoxic site.
Moreover, the local condition of bone marrow
has important role in EPC mobilization. The
cytokines of Granulocyte colony-stimulating
factor (G-CSF), matrix metalloproteinases-9
(MMP-9), VEGF, SDF- l , endothelial nitric
oxide synthases (eNOS) and Nitric oxide (NO)
induce mobilization by interfering the interaction
between EPC and the stroma cells of bone
manow, which allow EPCs to be released from
bone rnarrow through endothelial sinusoid and
entering the blood circulation. The process is
the initial phase ofEPCs mobilization from the
bone marrow.r2'll
The process of EPCs differentiation into
mature endothelial cells is still poorly understood.
Various studies found that VEGF induces
EPCs differentiation and the process of EPCs
differentiation into mature endothelial cells has
occuned gradually since the migration ofEPCs
from bone marrow to the systemic circulation.r0 ra
As a response to proinflammatory cytokines
released by hypoxic tissue, endothelial cells will
increase the expressions of adhesion molecules
cells such as E-sellectin, intercellular adhesion
molecule- 1 (ICAM-l), vascular adhesion
molecule-l (VCAM-1) and pl-integrin, which
facilitate EPCs attachment to local endothelial
cells. Next, the EPCs secrete MMPs and
matrix metalloelastases (MMEs), which locally
impair extracellular matrix and it initiates
neovascularization. r2
Morphologically, EPCs cannot be identified,
but there are some specific markers that can be
used. ln the early phase, the cells showed positive
response to CD133, CD34 and VEGFR-2. Cells
that shows positive response to those three
markers are mainly still in the bone marrow;
while the cells which are already present
in peripheral circulation show diminishing
expression of CDl33; however, the expressions
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of CD34 and VEGFR-2 are still present. The
next de{elopment is the advance phase of EpC
(the mature endothelial cells), in which the
expression of CD34 has diminished, but the
VEGFR-2 is still positive and the expressions of
vascular endothelial cadherin (VE-cad), platelet
endothelial cell adhesion molecule- 1 (PECAM- 1/
CD3l) and von Willebrand facror (vWF) is
initiated.r3-r5 Markers of EPCs mobilization
include SDF-1, MMP-9, GCS-F and eNOS.
Marker which shows the quantity of EpCs is the
expression of total CD34; while the marker for
EPCs quality are viable CD34, VEGFR-2 and
EPC culture cells.13
ENDOTHELIAL DYSFUNCTION AND THE
ROLE OF EPC
Endothelial cell is a layer of cell covering
the inner side of vascular wall. The cell responds
to each physical or chemical stimulation by
releasin$ appropriate sqbstances to maintain
vasomotor balance and vascular hemostasis. A
condition, in which the endothelial cell loses
its ability to maintain the balance and when
the endothelial cells have lost its physiological
capacity.to promote iasodilation, fibrinolysis
and antiagregation effect, is called as endothelial
dysfunction.ra'rb
The pathophysiology of endothelial
dysfunction is very complex and involves
various mechanism through oxidative stress,
i.e. a condition with increased reactive oxygen
species (ROS) production and reduced
antioxidant level. Increased ROS causes
deprivation in NO availability, i.e. a substance
produced by endothelial cells through eNOS
activation.16 Nitrii oxide not only has a role
in EPCs mobilization, but it also has a role in
EPCs migration and proliferation.16 Moreover,
increased pxidative stress will initiateNF-rcB that
may lead to inflammatory process as a beginning
of atherosclerosis process. r?
There is a dynamic correlation between
inflammation, oxidative stress and EpCs
mobilization. Oxidative stress stimulates
inflammatory process, in which proinflammatory
cytokines will stimulate the production of
growth factors such as VEGF, that will further
stimulate EPCs mobilization to the circulation.
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Inflammation may have good and bad impacts on
EPCs. The limited and temporary inflammatory
response can stimulate EPCs mobilization; while
excessive and continuous response will cause
reduced EPCs in the circulation. An in vitro
study has demonstrated that inflammation and
oxidative stress may affect EpC mobilization.
The presence of continuous factors causes
damages or continuous endothelial dysfunction
which may ultimately cause reduction or
exhaustion in EPCs supply.t3
The number of EPCs in the circulation
has negative cgrrelation with the degree of
endothelial dysfunction in patients with various
cardiovascular risk factors. There is a correlation
between the number of EPCs and endothelial
dysfunction, i.e. reduced number of EpCs can
predict the incidence of cardiovascular disease
in the future.r8,re
The role of EPCs in vascular repair is through
normalization of endothelial function and
improvement of blood flow in injured vascular
area. Since endothelial cells are mature cells
which has poor capacity to proliferate, i.e. only
about 0.01%,20 therefore, EPCs play an important
role in maintaining endothelial layer through
reendothelialization and neovascul arization. It
also indicates that EPCs can be used as a potential
therapy for treating endothelial dysfunction.2r
CONDITION AND FACTORS AFFECTING THE
NUMBERAND FUNCTION OF EPCS
The number of EPCs in the circulation
of healthy individual is very limited, i.e. less
than Io/o of total bone marrow cells and less
than 0.01/6 of total mononuclear cells in
peripheral blood; however various factors and
conditions can affect its number and function.6
Evidences of some studies show that patients
with cardiovascular risk factors such as age,
sex, smoking habits, hypertension, diabetes
mellitus (DM) and dyslipidemia have reduced
number and function of F.pCs. In contrast, some
cytokines, hormones, medicines and physical
activity can improve its number and function.ilA
study has demonstrated that the number of EpCs
is increased significantly for a short of time after
acute myocardium infarction (AMD attack and
it reaches peak level on the seventh day after the
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attack and subsequently, the level decreases.22
Another study that evaluated the number of
CD34+ cells in patients with heart failure shows
that there is increasing biphasic response, i.e.
increased CD34+ cells in patients with Class I
New York Heart Association (NYHA), but it is
reduced in patients with Class IV NYHA and
the numberris even lower when compared with
control.23 |
There are physiological conditions affect the
number and function of EPCs. which include
different age, sex and physical activity. Estrogen
has been known as a rapid stimulator for
endothelial NO production and eNOS activation.
In addition, estrqgen can also lower the level
of endogenous asymmetric dimethylarginin
(ADMA), which is the inhibitor of eNOS.2a
Fandini et al2s have reported that the number
of EPC is greater in fertile female than male
subjects; however, the difference has not been
found in postmenopausal women compared
to men of the same.age. fhei difference can
represent the risk of cardiovascular risk in men
and postmenopausal women, in which it is
correlated to the low number of EPCs.
In aging process, there is also an imbalance
between pYoduction of free radicals and the
availability df antioxidant. There is a correlation
between ROS, inflammation and age, i.e.
increased ROS level will potentially stimulate
chronic inflammation that ultimately will cause
impaired EPCs mobilization. Thus, it has also
been reported that there is reduced response
of EPC migratiorl to VEGF in elderly age as
well as reduced clonogenic capacity of EpC
that has begun starting from the middle age.26
Heiss et al21 have reported that the survival,
migration and proliferation capacity of the EpCs
are lower in those with older age. The findings
show that there is a negative effect of age on
EPC differentiation and proliferation, which is
correlated to cardiovascular risk.
Physical exercise causes increased NO
production. In a study that evaluate the effect of
physical exercise on EPC in patients with stable
coronary artBry disease (CAD), it found that
the number df EPC in the circulation increases
significantly and the apoptosis is reduced after
physical exercise for 28 days compared to the
first day of exercise. Increased EPC number
is correlated to higher NO availability after
physical exercise. The study demonstrates that
physical exercise increases the number of EPC
in bone maffow and peripheral blood, in which
the upregulation of EPC in physical exercise
depends on NO and VEGF.28
Smoking is one of risk factors causing
endothelial dysfunction. The high level of
oxidative stress in smoker can potentially affect
EPC mobilization and survival in vivo, in
which there is 500% reduction of EPC number in
smokers compared to the control.2e
Hypertension is also characterized by
endothelial dysfunction and reduced NO
availability. Endothelial dysfunction in patients
with early stage of hypertension can induce the
development of EPCs mobilization factor as
the mechanism of compensation in the body.
In the advanced stage of hypertension, which
has continuous process of oxidative stress and
inflammation, it will give contrary effect, i.e.
reduced quality and quantity of EPCs.2,r3 In
patients with hypertension there is accelerated
aging of EPCs and reduced activity of telomerase
that affect vascular remodeling. 30
Dysfunction of EPCs in hypertension
causes endothelial repair and neoangiogenesis
cannot take place and it will worsen the
microvascular abnormality and atherosclerosis,
which is the beginning of target organ damage
in hypertension.3r In a study of subjects with
refractory hypertension, the number of EpCs
was reduced to76.7o/o compared to the control.32
Angiotensin II accelerates the onset of EpCs
aging through increased oxidative stress.33 A
clinical trial in CAD patients has demonstrated
that ramipril can increase the number of EpCs
2-5 folds as well as its function.3a Treatment
using angiotensin II receptor antagonist also
increases the number of EPCs significantly, in
which olmesartan treatment can cause increased
EPCs from 231+24 to 465+7I; while irbesartan
treatment increases the number from 196+15 to
300+23 after 4-week treatment.35
In patients with type I and type 2 DM,
there is reduced number and function of EpC in
circulation. Tapper et al36 have demonstrated that
isolated EPCs from peripheral blood of patients
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with type 2 DM have reduced proliferation
capacity in the culture up to 48o/o compared to
normal individuals. Loomans et al37 also have
reported similar results in patients with type I
DM, i.e. there is reduced EPCs number of 440/o
compared to the non-diabetics control group.
There is a significant increase of EPCs number
in DM patients who were treated with insulin
or oral diabetic agents.38 insulin stimulates NO
production; while in insulin resistance, there is
an imbalance between endothelial damage and
the ability of repair. This condition is correlated
to reduced availability of NO, increased ROS
production and PI3IOAkI down-regulation. It is
potentially disrupt the process of vascular repair,
which is the role of EPCs, including impaired
EPC mobilization from the bone marrow'3e
Increased plasma cholesterol level has
signifi cant correlation with endothelial damage
and dysfunction. It has bepn proven that the
number of EPCs'is red'rced significantly in
patients with hypercholesterolemia and the
number of EPCs has negative correlation with
the level of total cholesterol and low density
lipoprotein (LDL) cholesterol.a0
Anti-inflammatory agents and antioxidants
such as HMG-CoA reductase inibitors(statin)
have been proven to have positive effects
on EPC. Statin increases mobilization and
function of EPC through upregulation of PI3K/
Akt. The effect of statin in mobilizing EPC
to the circulation is correlated with increased
reendothelialization and reduced neointima
resulting in reduced restenosis.ar'a2
CLINICAL APPLICATION OF EPCs
Several sfudies have been conducted to sound
out the application of EPCs in clinical settings'
Although the basic biomolecular mechanism
of EPCs has pot been fully understood, some
studies have shown promising results. Increasing
EPCs number in the circulation is essential as it
coruelates positively with reendothelialization
and neovascularization, which has strong
association with cardiovascular health'26
The use of EPCs as target therapy is based on
the results of some studies such as: local injection
or infusion of fresh CD34+ cells isolated from
human can accelerate the blood flow to the
344
Acta Med Indones-Indones J Intern Med
ischemic area in diabetic experimental animal
model. In a clinical trial, EPCs transplantation
to those with myocardium infarct, ischemia,
coronary arterial disease and heart failure has
been proven to be appropriate and safe.a3
EPCs transplantation is one of promising
strategies for restoring blood flow in ischemic
diseases such as ischemic heart disease and
peripheral artery disease (PAD).44 In a study
of transplantation of progenitor cells and
regeneration enhancement in acute myocardial
infarction (TOPCARE-AMI), EPCs was given by
intracoronary infusion to 20 patients with acute
myocardium infarction. The study shows that
there is significant increase ofejection fraction,
smaller area of infarction and better perfusion of
myocardium.a5 As a target therapy, in addition
to its benefit for additional vascularization in
ischemic tissue, it can also be used to deliver
anti- or pro-angiogenic agents.3
The very limited number of EPCs will limit
the use of EPCs as a therapy. The number of
EPCs needed for therapy in human adults is
relatively large, i.e. about 3x108 to 6x108 cells,
which means that 8.5-120 liter of peripheral
blood is necessary to generate adequate number
of EPCs.a6 To overcome the limitation, we need
an effort to expand the number of EPCs.
Some strategies that have been considered
as applied EPCs for treatment are:aa 1) In vivo
expansion of EPCs. Some candidates canbe used
to induce EPC in vivo such as VEGF, GM-CSF
and statin; 2) Ex vivo expansion of EPC. The
strategy is performed by taking mononuclear
cells from peripheral blood of healthy individual
and then the cells are cultured. After obtaining
suffrcient number of EPCs, the EPCs are then
injected to ischemic area;3) Local injection of
EPC. Local injection of SDF-1 can increase the
accumulation of the transplanted EPCs resulting
in increased neovascularization. Combination of
SDF-1 local injection and EPCs transplantation
is a potential strategy for neovascularization
therapy; 4) EPCs modification through gen
transfer. Various studies have been conducted
and still on going to enhance the effort of EPC
expansion including by genetic engineering,
i.e by transferring human telomerase reverse
transcriptase (hTERT) gene or coding genes for
I
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proangiogenesis factor such as VEGF into EPCs'
THE PROGNOSTIC VALUE OF EPCs
There is a correlation between the number of
EPCs and 
"indoth.liul 
dysfunction, i.e. reduced
number of EPCs can predict the incidence
of cardiovascular disease in the future. The
number EPCs isolated from the patients with
cardiovascular risk factors has a significant
negative correlation with the risk factor score
based on the Framingham score.aT
EPCs level i{ an independent predictor for
mortalify due to chronic heart failure, in which
the level is not affected by the etiologies of
heart failure, instead it is more correlated to
clinical status of the patient evaluated by NYHA
classification. EPCs level has been suggested to
be an additional marker for clinical follow up of
patients with chronic heart failure.a8
The number of EPCs in the circulation is
extremely reduced in patients.with type 2 DM,
metabolic syndrome and individuals with insulin
resistance. In those with metabolic syndrome, the
EPCs levelihas negative correlation with HOMA
score. The level of EPC in patients with type 1
and type 2 DM also has negative correlation with
HbAIC level.47'28'62
CONCLUSION
Endothelial progenitor cell can be isolated
from peripheral blood, in which the cells undergo
differentiation into mature endothelial cells and
are involved in reendothelialization as well as
neovascul ar ization in endothelial dysfunction.
The cells is usually identified through positive
expressions of CDl33, CD34 and VEGFR-2'
EPCs mobilization from bone marrow and its
number in circulation is extremely affected by
endogenous and exogenous factors as well as
physiological and pathological conditions. The
cells have important roles in prevention and
therapy of cardiovascular diseases. The higher
the numbbr of endothelial progenitor cells in
circulation, the more protective it is for blood
vessels, particularly reendothelialization and
neovascularization of ischemic tissue and EPCs
can be used as a predictor of cardiovascular
disease in the future.
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